Study objective: To determine whether the prognostic value of dobutamine stress echocardiography (DSE) performed early after acute myocardial infarction (AMI) is as high in diabetic patients as in nondiabetic patients. Design: Inception cohort study. Setting: Tertiary cardiac referral center. Patients and interventions: Three hundred thirty-eight patients (116 diabetic and 222 nondiabetic) who underwent DSE after AMI were followed up for cardiac events. Measurements and results: Outcome events were as follows: "hard" events consisted of cardiac death and nonfatal reinfarction, while "all events" included hard events and unstable angina. The mean follow-up duration was 21 ؎ 9 months. DSE results were positive in 69 diabetic patients (59.5%) and 129 nondiabetic patients (58.1%; p ‫؍‬ 0.817). During the follow-up period, there were 25 cardiac deaths, 16 cases of nonfatal reinfarction, and 55 cases of unstable angina. The Kaplan-Meier life table showed that a positive DSE result was associated with a lower event-free survival rate in nondiabetic but not in diabetic patients in terms of hard and all events. By multivariate analysis, a positive DSE result was the strongest independent predictor of future cardiac events in nondiabetic patients. However, in diabetics, a shorter dobutamine time, rather than a positive DSE result, independently predicted cardiac events. Conclusions: Our preliminary data suggest that different DSE variables should be considered when assessing the likelihood of future events in diabetic and nondiabetic patients after AMI. The observation of shorter dobutamine time, instead of DSE positivity, has a higher prognostic value in diabetics. In diabetic patients, the only significant role of DSE positivity is for predicting future unstable angina; however, its predictive value is not as good as in nondiabetic patients.
P
atients with diabetes mellitus have an increased risk of cardiovascular morbidity and mortality. The prognosis in diabetic patients is also worse than in nondiabetic patients at both 30 days and at 1 year after acute myocardial infarction (AMI). 1 In addition, several studies [2] [3] [4] [5] [6] have confirmed that diabetes is associated with a higher rate of coronary lesion progression, occlusion, plaque ulceration, thrombosis, and formation of new narrowings, all of which suggest that the characteristics of vascular disease are different in diabetic and nondiabetic patients.
Recently, dobutamine stress echocardiography (DSE) has become an established method to predict future cardiac events after AMI. 7, 8 Ischemic areas detected by DSE are thought to be sites with increased risk of future cardiac events. However, due to the diffuse, accelerated atherosclerosis with hypercoagulable state in diabetic patients, the lesions responsible for future cardiac events may be different from those detected in a prior DSE. Thus, the more unstable nature of the vascular characteristics in diabetic patients may affect the ability of DSE to predict specific future cardiac events. To date, data on the prognostic value of DSE in diabetic patients after AMI are still lacking. In this study, we compared the prognostic value of DSE in diabetic and nondiabetic patients following AMI.
Materials and Methods

Subjects
From February 1995 to August 1997, 354 consecutive patients who were referred (after their first AMI) for assessment of cardiac risk and extent of residual myocardial ischemia were prospectively enrolled in the study. Diabetes mellitus was present in 126 patients (35.6%). Patients were included in the diabetic group if they received active treatment for diabetes mellitus with either insulin or an oral hypoglycemic agent at the time of DSE. Patients in whom the glucose level was controlled by diet were included in the diabetic group only if a fasting blood glucose level of Ͼ 140 mg/dL (7.77 mmol/L) or a random blood glucose level of Ͼ 200 mg/dL (11.1 mmol/L) was reported during hospitalization for the first AMI. 9 All other patients who did not fulfill these criteria were included in the nondiabetic group.
AMI was documented on the basis of typical chest pain lasting Ͼ 30 min, elevated serum creatine kinase and MB subform levels at least twice the normal value, and an elevated ST-segment Ն 1.0 mm in more than two contiguous limb leads or Ն 2.0 mm in more than two contiguous precordial leads, respectively. Peripheral arterial disease was defined by duplex and color Doppler ultrasonography in patients with either claudication or a nonhealing lower extremity ulcer. Congestive heart failure was evaluated before discharge according to the New York Heart Association (NYHA) classification. 10 Patients with previous myocardial infarction, severe valvular heart disease, nonsinus rhythm, history of percutaneous coronary angioplasty, bypass surgery, NYHA functional class IV, or poor echocardiographic image quality were excluded from the study.
Dobutamine Stress Test
DSE was performed 14 Ϯ 8 days after AMI using an echocardiographic system (Sonos 2500; Hewlett-Packard; Andover, MA) with a 2.5 MHz transducer, and was digitized online using TomTec Integrated Cardiac Analysis Software (Tom Tec Imaging Systems; Boulder, CO). All cardioactive drugs were withdrawn at least five half-lives before DSE. With the patient reclining in the left lateral decubitus position, baseline hemodynamic, ECG, and echocardiographic data were collected. Dobutamine was then infused into a peripheral vein using an incremental regimen of 5, 10, 20, 30, and 40 g/kg/min (3 min/dose). IV atropine (0.5 to 1.0 mg) was added if patients did not achieve 85% of their agepredicted maximal heart rate and had no symptoms or signs of ischemia. Two-dimensional echocardiograhic images in the four standard views were continuously acquired during each dose of dobutamine infusion and for at least 5 min after the end of the infusion. Images were recorded in a quadscreen format and stored on an optic disk for analysis. BP, heart rate, and ECGs were monitored throughout the study. End points included achievement of peak stress, development of severe ischemia, ST-segment elevation, hypertension (systolic BP Ͼ 230 mm Hg), significant arrhythmia, or any severe complication.
Stress Echocardiography
Images were analyzed using the standard 16-segment model and four-point scoring system (1 ϭ normal; 2 ϭ hypokinetic; 3 ϭ akinetic; 4 ϭ dyskinetic). The wall motion score index (WMSI) was derived by dividing the sum of individual segment scores by the number of interpretable segments. Myocardial ischemia was considered to be present when there were new regional wall motion abnormalities, worsening of the segmental score by more than one, or biphasic wall motion changes (defined as an initial improvement at low-dose dobutamine stress with subsequent worsening at peak stress). Test positivity was classified as homozonal (ischemia induced within the infarct zone), remote zone, or both. The dobutamine time was defined as the test duration (in minutes) from the start of the test to echocardiographically detected ischemia. Image interpretation was performed independently by two experienced observers without knowledge of the clinical, ECG, or angiographic data. Disagreements were resolved by consensus. The intraobserver and interobserver agreements were 94% and 90%, respectively.
Cardiac Catheterization
Selective coronary angiography using the Judkins technique was performed in 263 patients (77.8%) within 1 week after AMI. The angiograms were reviewed by two expert intervention cardiologists who were unaware of the patients' clinical data. The degree of coronary stenoses was expressed in terms of percent diameter reduction; the diameter of the most stenotic region was compared with a normal-appearing region proximal to the region of stenosis. A Ͼ 50% reduction was considered significant. In patients in whom there was a discrepancy of Ͼ 5% stenosis, the luminal diameter was determined by the caliper technique.
Patient Follow-up
For all patients, follow-up data were obtained from hospital records, personal communication with the patients' physicians, telephone interviews, and patients' visits to staff physicians at regular intervals in the outpatient clinic. "Hard" outcome events were cardiac death and nonfatal reinfarction, while "all events" included hard events and unstable angina. Cardiac death was defined as death with documentation of significant arrhythmia or cardiac arrest, or both, or death attributable to congestive heart failure or myocardial infarction in the absence of any other precipitating factors. For patients who died outside of the hospital and did not receive an autopsy, sudden unexpected death was attributed to a cardiac cause. The recurrence of AMI was defined using the standard criteria of history, ECG, and cardiac enzyme levels. Unstable angina was defined as accelerating anginal symptoms requiring hospital readmission, or progression of symptoms requiring revascularization. Because the decision for bypass surgery and coronary angioplasty might be subjective, the outcomes of patients with revascularization were excluded from the final data analysis. Only the most severe outcome was considered an end point during the follow-up period after patients with planned revascularization were excluded.
Statistical Analysis
Results are expressed as mean Ϯ SD for continuous variables and as percentages for categorical variables. Baseline variables and the positive and negative predictive values of DSE for future events were compared between groups using the 2 or t test. The predictive values of several clinical and DSE variables for event-free survival were evaluated by a stepwise Cox regression analysis. Relative risk and 95% confidence intervals were also calculated. The relative risk of dobutamine time was determined after every additional infusion minute. The event-free survival (Kaplan-Meier) of patients with a negative DSE result was determined, and the differences between survival curves were tested with the log rank test. The Cox proportional regression model was used to identify significant independent predictors of new cardiac events, including age, gender, hypertension, smoking, peripheral arterial disease, left ventricular ejection fraction, tissue plasminogen activator treatment, infarct area, Killip classification, NYHA functional class (I vs II and III), WMSI at rest and peak stress, dobutamine time, and positive DSE result. All statistical analyses were performed using appropriate software (SPSS for Windows, Release 6.0; SPSS; Chicago, IL). A p value Ͻ 0.05 was considered statistically significant.
Results
Of a total of 354 patients with AMI, 16 were excluded from the study because of intolerance to dobutamine stress (n ϭ 5), hypertension (n ϭ 5), dobutamine extravasation (n ϭ 3), or atrial fibrillation induced during dobutamine stress (n ϭ 3). The remaining 338 patients were included in the final analysis. Of these, 116 patients (34.3%) were diabetic and 222 patients (65.7%) were nondiabetic.
Baseline Characteristics
As compared to the nondiabetic patients, diabetic patients had a higher percentage of female gender, they more frequently had a history of hypertension and peripheral arterial disease, and they had a lower prevalence of smoking ( Table 1 ). The frequencies of triple vessel disease and NYHA functional class III were significantly greater in the diabetic group. Although there was no significant difference in the left ventricular ejection fraction between the two groups, the resting WMSI in the diabetic group was slightly higher than in the nondiabetic group. The infarct location, Killip class, dobutamine time (the time to ischemia), and the rate of DSE positivity were similar in the two groups.
DSE
DSE was performed smoothly in all patients. Atropine was added in addition to dobutamine in 19 diabetic patients and 27 nondiabetic patients (15.5% vs 12.2%, respectively; p ϭ 0.283). Patients in the diabetic group had an insignificantly higher rate of heterozonal myocardial ischemia than nondiabetic patients (58.9% vs 47.9%, respectively; p ϭ 0.150), but a lower frequency of homozonal ischemia (69.8% vs 76.8%, respectively; p ϭ 0.322). Twelve patients in the diabetic group and 37 patients in the nondiabetic group received scheduled revascularization procedures (10.3% vs 16.7%, respectively; p ϭ 0.206). After excluding the 49 patients who received early scheduled revascularization procedures, 104 patients in the diabetic group and 185 patients in the nondiabetic group were included in the follow-up protocol ( Table 2 ). The mean follow-up period was 21 Ϯ 9 months. In diabetic patients with cardiac death, DSE results were positive in six patients (three died of reinfarction, two died of progressive heart failure, and one died suddenly outside the hospital) and negative in five patients (one died of reinfarction, three died of progressive heart failure, and one died suddenly). The frequencies of cardiac events, with the exception of unstable angina, were not significantly related to DSE positivity. Among the 10 cases of reinfarction, the infarct location was predicted correctly by DSE in 6 cases, but was not predicted correctly in 4 cases (2 with positive results and 2 with negative results).
Among the nondiabetic patients with cardiac death, DSE results were positive in 11 patients (6 died of reinfarction, 2 of progressive heart failure, and 3 sudden deaths) and were negative in 3 patients (2 died of progressive heart failure, and 1 of reinfarction). The frequencies of future reinfarction, unstable angina, and hard and all events were significantly greater in patients with positive DSE results than in those with negative DSE results ( Table 2 ). In the 17 cases of reinfarction, the infarct location was predicted correctly by DSE in 13 cases but not in 4 cases (2 with positive test results and 2 with negative test results). The accuracy of DSE in predicting the reinfarct location in the nondiabetic group was slightly, but insignificantly, better than in the diabetic group (76% vs 60%, respectively; p ϭ 0.415).
The cardiac-origin mortality rate in diabetic patients was slightly higher than in nondiabetic patients (10.5% vs 7.6%, respectively; p ϭ 0.382), especially for deaths related to progressive heart failure (4.8% vs 2.1%, respectively; p ϭ 0.215). The incidence of unstable angina and reinfarction in nondiabetic patients was insignificantly greater than in diabetic patients (30.8% vs 24.0%, respectively; p ϭ 0.226).
In addition, the sensitivity, specificity, and positive and negative predictive values of DSE for the prediction of future cardiac events were higher in the nondiabetic group than in the diabetic group, although the differences were not statistically significant (all p Ͼ 0.05; Table 3 ).
Hard Events
From the univariate analysis model, peripheral arterial disease (p ϭ 0.0006) and shorter dobutamine time (p ϭ 0.013) were associated with a lower event-free survival rate in diabetic patients, but a positive DSE result was not (p ϭ 0.874; Fig  1 top, A) . In nondiabetic patients, negative DSE results (p ϭ 0.0008; Fig 1 bottom, B) , lower peak stress WMSI (p ϭ 0.002), lower number of diseased vessels (p ϭ 0.003), higher ejection fraction (p ϭ 0.005), treatment with tissue-type plasminogen activator (p ϭ 0.014), lower Killip classification (p ϭ 0.031), and nonanterior infarct (p ϭ 0.042) were associated with a better eventfree survival. The dobutamine time in diabetic patients with hard events was significantly shorter than those without hard events (12.9 Ϯ 2.9 vs 14.7 Ϯ 2.6, respectively; p ϭ 0.025); however, this significant difference was not observed in nondiabetic patients (13.8 Ϯ 2.9 vs 14.4 Ϯ 2.6, respectively; p ϭ 0.245). Multivariate stepwise analysis revealed that peripheral arterial disease and shorter dobutamine time, but not DSE positivity, independently predicted a worse outcome in diabetic patients (Table 4) . In nondiabetic patients, the WMSI at peak stress was the strongest independent predictor, followed by a positive DSE result.
All Events
The Kaplan-Meier life table showed that peripheral arterial disease (p ϭ 0.014) and shorter dobutamine time (p ϭ 0.0001) were associated with a lower event-free survival rate in patients with diabe- tes, but a positive DSE result was not (p ϭ 0.068; Fig 1 top, A) . In the nondiabetic group, patients with negative DSE results (p Ͻ 0.0001; Fig 1 bottom, B) , lower WMSI at rest (p ϭ 0.0001) or peak stress (p Ͻ 0.0001), lower numbers of diseased vessels (p ϭ 0.003), current smokers (p ϭ 0.033), and longer dobutamine time (p ϭ 0.037) had a better event-free survival. The dobutamine time in diabetic patients with all events was significantly shorter than those without all events (12.6 Ϯ 2.9 vs 15.2 Ϯ 2.2, respectively; p Ͻ 0.0001); however, this significant difference was not observed in nondiabetic patients (13.9 Ϯ 3.1 vs 14.5 Ϯ 2.4, respectively; p ϭ 0.231). Multivariate stepwise analysis revealed that a shorter dobutamine time, but not a positive DSE result, independently predicted a worse outcome in diabetic patients (Table 4) . In nondiabetic patients, a positive DSE result was the strongest independent predictor, followed by the WMSI at peak stress.
Discussion
The results of the present study reveal that a positive DSE result has a powerful prognostic value for both hard events and all cardiac events following AMI in patients without diabetes. However, in diabetic patients, the prognostic value of a positive DSE result was lower for both cardiac death and reinfarction. The only significant role of DSE in diabetic patients is for predicting future unstable angina; however, the predictive value is not as good as in the nondiabetic group.
Previous Studies in Diabetic Patients
Focusing on patients with diabetes, many investigators 11, 12 found that DSE has a high diagnostic sensitivity but low specificity for coronary artery disease, and they attributed this finding to the possible underdetection of small vessel disease by coronary angiography. In postmyocardial infarction patients, Mak et al 1 found that the presence of diabetes is significantly and independently associated with 1-year mortality after myocardial infarction. Diabetic patients were also found to have more diffuse coronary artery disease as assessed by the mean number of coronary artery segments, with at least one stenosis of Ն 25%. 5 Furthermore, a significant increase in plaque ulceration and thrombosis was found at angioscopy in diabetic patients. 6 Recent reports also revealed that the restenosis rate and speed of disease progression in diabetic patients receiving revascularization procedures are much higher and faster, respectively, than in nondiabetic patients. 3, 4 These data all suggest that the prognostic value of DSE will be influenced by the presence of diabetes.
Differences in the Cardiac Events Between Diabetic and Nondiabetic Patients
Similar to many previous reports, 1,3,13,14 our study showed that diabetics more frequently were of the female gender and more commonly had hypertension, peripheral arterial disease, and triple vessel disease. These different baseline characteristics could affect the adverse event rate in diabetics. In this study, although the left ventricular ejection fraction in diabetic patients was not significantly lower than in nondiabetic patients, those with diabetes had more advanced congestive heart failure symptoms, which has been suggested to be associated with an adverse prognosis after myocardial infarction. 4, 14 In addition, our data revealed a trend of diabetic patients having higher cardiac-origin death rates and more cardiac deaths due to progressive heart failure than nondiabetic patients, which is consistent with previous reports. 1, 13, 14 
DSE in Detecting Myocardial Ischemia in Diabetic Patients
Previously, Calnon et al 15 found that the ischemic pattern induced by dobutamine stress in subjects with more severe coronary disease is characterized as "failure to increase systolic thickening during dobutamine stress". Lu et al 16 also found that DSE results are associated not only with stenosis severity but also, even more importantly, with lesion morphology. Furthermore, many investigators [17] [18] [19] who evaluated the prediction of multivessel disease by DSE in patients with resting left ventricular asynergy consistently reported a high specificity but a low and markedly varied sensitivity. These findings suggest that the diagnostic value of DSE using the present criteria of detecting myocardial ischemia is not satisfactory, and could explain why the rate of positive DSE results was similar between the two groups, *There were no significant differences between diabetic and nondiabetic groups (p Ͼ 0.05).
despite a higher frequency of triple vessel disease and a trend of more left ventricular asynergic segment in diabetic than in nondiabetic patients.
DSE in Predicting Future Events in Diabetic Patients
Many investigators have found that coronary atherosclerotic lesions are not only prone to narrowing, but also tend to become unstable or develop into coronary occlusions in patients with diabetes. [2] [3] [4] [5] [6] 20 Furthermore, in patients after uncomplicated AMI, a history of diabetes mellitus, regardless of DSE positivity, has also been shown to be an independent predictor of future spontaneous cardiac events. 14, 21 These findings suggest that hard events (eg, AMI or cardiac death) would be prone to occur in diabetic patients. Our data show that the only significant role of DSE in diabetic patients is for predicting future unstable angina; however, the predictive value is not as good as in the nondiabetic group. This might have been due to a higher incidence of silent angina in diabetic patients.
Predictors of Cardiac Events in Diabetic and Nondiabetic Patients
In the diabetic group, the dobutamine time and presence of peripheral arterial disease were both independent predictors of cardiac events. The time to ischemia (the ischemic threshold), has been used as an index of disease severity with both the dipyridamole 22 and dobutamine 23 regimens. Many studies 22, 24 using dipyridamole or dobutamine echocardiography have emphasized the important role of the dipyridamole or dobutamine time. Some investigators 16, 25 have found that a relationship exists between complex lesion morphology and pharmacologic echocardiography test positivity, indicating that the physiologic consequences of a stenosis cannot always be predicted with a simple anatomic approach. With appreciation that coronary stenosis severity is not the only variable of coronary stenosis, it is suggestive that dobutamine time (the ischemic threshold) is not the same for simple and complex coronary lesions. Therefore, DSE with a lower ischemic potential may not reach the ischemia ceiling in the presence of simple coronary artery lesion morphology. On the other hand, in patients with complex coronary artery lesions of similar severity, the ischemic ceiling may be reached with shorter dobutamine stress time. Because of the additive effect of the accelerated and diffuse nature of atherosclerotic disease, and the more complex coronary artery lesion morphology in diabetics, patients with shorter dobutamine time comprise a subgroup at very high risk of future cardiac events.
In nondiabetic patients, DSE positivity and peak stress WMSI were both independent predictors of future events. This is consistent with previous DSE studies, 7, 15 most of which consisted of a high percentage of nondiabetic patients. The culprit lesions detected by DSE could be the lesions of future cardiac events in nondiabetic patients who have fewer diseased vessels, fewer new lesions, and slower disease progression. Although univariate analysis revealed that nondiabetic patients with a longer dobutamine time had a better event-free survival, the prognostic value of dobutamine time was decreased in the multivariate analysis.
Noninvasive Risk Stratification in Patients after AMI
Several noninvasive modalities of stress testing are widely used for the functional and prognostic assessment of patients following AMI. The predischarge exercise ECG can reflect the risk of subsequent ischemic events when no preexisting ST-segment abnormalities are present. 26 However, because of its limited diagnostic sensitivity, the requirement for no preexisting ECG changes, and the reduced exercise capacity of patients after AMI, exercise ECG is not as good as either the stress scintigraphy or the stress echocardiography. 27, 28 Treadmill stress echocardiography also provides useful information for assessing the risk of subsequent ischemic events, such as exercise endurance and time to the development of symptoms, and is therefore helpful in providing indicators for proper exercise rehabilitation. However, pharmacologic stress tests are more suitable for those patients who do not have the physical function to perform treadmill stress tests. Compared to stress scintigraphy, the diagnostic accuracy of DSE is more dependent on the quality of echocardiographic images and the physician's experience in interpreting them, but there is more information obtained from echocardiographic evaluation at peak stress and the ischemic threshold as assessed by dobutamine time. There are no reported data comparing the prognostic value of DSE and stress scintigraphy in predicting future cardiac events in diabetic patients following AMI. In general, exercise and pharmacologic stress echocardiography are less costly than radionuclide stress scintigraphy. As the experience in this study shows, an early (1 week after AMI) or predischarge DSE is safe and valuable in the risk stratification for further cardiac outcomes.
Study Limitations
There are some important limitations of this study. Because relatively few cardiac events occurred, a definite conclusion on the prognostic value of DSE in diabetic patients cannot be obtained. The patient numbers were relatively small, and a larger sample of diabetic patients may provide more information. Despite the relatively small sample of patients, we were able to show that the diabetic patients with a shorter dobutamine time during DSE constitute a subgroup at risk of future cardiac events after AMI. Also, data were analyzed from a single center, which could decrease the interinstitutional variation when interpreting results of DSE and collecting follow-up data. However, these patients were evaluated in a tertiary referral center, and this takes the advantage of a homogenous reading in a single echocardiographic laboratory. In addition, treatment decisions were not made in a fashion blinded to the presence or absence of diabetes, and this might have influenced the outcome of the patients.
Clinical Implications
It is necessary to integrate all of the information available to the clinician in deciding how to proceed with both diabetic and nondiabetic patients. Our preliminary data suggest that different DSE variables should be considered when assessing the likelihood of future events in diabetic and nondiabetic patients. The observation of dobutamine time, instead of DSE positivity, has a higher prognostic value in diabetics. The only role of DSE positivity in diabetic patients is for predicting future unstable angina; however, the predictive value is not as good as in the nondiabetic patients.
